Rebecca F Gottesman1,2, Thomas H Mosley3, David S Knopman4, Qing Hao5, Dean Wong6, Lynne E Wagenknecht7, Timothy M Hughes8, Ye Qiao6, Jennifer Dearborn9, Bruce A Wasserman6. 1. Department of Neurology, Johns Hopkins University, Baltimore, Maryland. 2. Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland. 3. Department of Medicine, University of Mississippi Medical Center, Jackson. 4. Department of Neurology, Mayo Clinic, Rochester, Minnesota. 5. Department of Neurology, Mount Sinai Medical Center, New York, New York. 6. Department of Radiology, Johns Hopkins University, Baltimore, Maryland. 7. Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina. 8. Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina. 9. Department of Neurology, Beth Israel Deaconness Medical Center, Harvard Medical School, Boston, Massachusetts.
Abstract
Importance: Intracranial atherosclerotic disease (ICAD) is an important cause of stroke and has also been recently identified as an important risk factor for all-cause dementia, but the mechanism of its association with cognitive performance is not fully understood. Objective: To test the hypothesis that ICAD is associated with cerebral β-amyloid deposition as a marker of Alzheimer disease. Design, Setting, and Participants: This cross-sectional analysis of data collected from August 2011 through November 2014 was a community-based cohort study conducted in 3 US communities. Of 346 adults without dementia aged 70 to 90 years who were sequentially recruited from 3 of 4 sites of the larger Atherosclerosis Risk in Communities study into a study of brain florbetapir positron emission tomography (ARIC-PET), 300 met inclusion criteria. A total of 589 were approached about recruitment, of whom 346 (58.7%) consented (the remainder either met exclusion criteria for ARIC-PET or refused to participate). Data were analyzed from July 2017 through October 2019. Exposures: Intracranial atherosclerotic disease presence, frequency, and extent of stenosis, by high-resolution vessel wall magnetic resonance imaging. Main Outcomes and Measures: Global cortical standardized uptake value ratio (SUVR) of greater than 1.2 as measured by florbetapir PET. Models were conducted using logistic regression methods. In secondary analyses, we tested effect modifications by apolipoprotein E ε4 genotype with interaction terms and in stratified models and evaluated regional patterns of associations. Results: In 300 participants (mean [SD] age, 76 [5] years; 132 African American individuals [44%], 167 women [56%], and 94 carriers of at least 1 apolipoprotein E ε4 allele [31%]), ICAD was found in 105 participants (35%) and mean (SD) SUVR was higher in individuals with vs without intracranial plaques (1.34 [0.29] vs 1.27 [0.23]; P = .03). In adjusted models, ICAD presence (plaque presence [adjusted odds ratio (aOR), 1.20; 95% CI, 0.69-2.07] and frequency [aOR, 1.10; 95% CI, 0.96-1.26]) was not associated significantly with elevated SUVR in the total sample. Furthermore, modest stenosis of the intracranial vessels (defined as >50% stenosis) was not associated with elevated SUVR (aOR, 2.33; 95% CI, 0.82-6.60). Conclusions and Relevance: In this community-based cohort of adults without dementia, intracranial atherosclerotic plaque or stenosis was not associated with brain β-amyloid deposition.
Importance: Intracranial atherosclerotic disease (ICAD) is an important cause of stroke and has also been recently identified as an important risk factor for all-cause dementia, but the mechanism of its association with cognitive performance is not fully understood. Objective: To test the hypothesis that ICAD is associated with cerebral β-amyloid deposition as a marker of Alzheimer disease. Design, Setting, and Participants: This cross-sectional analysis of data collected from August 2011 through November 2014 was a community-based cohort study conducted in 3 US communities. Of 346 adults without dementia aged 70 to 90 years who were sequentially recruited from 3 of 4 sites of the larger Atherosclerosis Risk in Communities study into a study of brain florbetapir positron emission tomography (ARIC-PET), 300 met inclusion criteria. A total of 589 were approached about recruitment, of whom 346 (58.7%) consented (the remainder either met exclusion criteria for ARIC-PET or refused to participate). Data were analyzed from July 2017 through October 2019. Exposures: Intracranial atherosclerotic disease presence, frequency, and extent of stenosis, by high-resolution vessel wall magnetic resonance imaging. Main Outcomes and Measures: Global cortical standardized uptake value ratio (SUVR) of greater than 1.2 as measured by florbetapir PET. Models were conducted using logistic regression methods. In secondary analyses, we tested effect modifications by apolipoprotein E ε4 genotype with interaction terms and in stratified models and evaluated regional patterns of associations. Results: In 300 participants (mean [SD] age, 76 [5] years; 132 African American individuals [44%], 167 women [56%], and 94 carriers of at least 1 apolipoprotein E ε4 allele [31%]), ICAD was found in 105 participants (35%) and mean (SD) SUVR was higher in individuals with vs without intracranial plaques (1.34 [0.29] vs 1.27 [0.23]; P = .03). In adjusted models, ICAD presence (plaque presence [adjusted odds ratio (aOR), 1.20; 95% CI, 0.69-2.07] and frequency [aOR, 1.10; 95% CI, 0.96-1.26]) was not associated significantly with elevated SUVR in the total sample. Furthermore, modest stenosis of the intracranial vessels (defined as >50% stenosis) was not associated with elevated SUVR (aOR, 2.33; 95% CI, 0.82-6.60). Conclusions and Relevance: In this community-based cohort of adults without dementia, intracranial atherosclerotic plaque or stenosis was not associated with brain β-amyloid deposition.
Authors: Philip Scheltens; Bart De Strooper; Miia Kivipelto; Henne Holstege; Gael Chételat; Charlotte E Teunissen; Jeffrey Cummings; Wiesje M van der Flier Journal: Lancet Date: 2021-03-02 Impact factor: 79.321
Authors: Jose G Romano; Shyam Prabhakaran; Azhar Nizam; Edward Feldmann; Rajbeer Sangha; George Cotsonis; Iszet Campo-Bustillo; Sebastian Koch; Tatjana Rundek; Marc I Chimowitz; David S Liebeskind Journal: J Stroke Cerebrovasc Dis Date: 2020-12-01 Impact factor: 2.136
Authors: Aliza P Wingo; Wen Fan; Duc M Duong; Ekaterina S Gerasimov; Eric B Dammer; Yue Liu; Nadia V Harerimana; Bartholomew White; Madhav Thambisetty; Juan C Troncoso; Namhee Kim; Julie A Schneider; Ihab M Hajjar; James J Lah; David A Bennett; Nicholas T Seyfried; Allan I Levey; Thomas S Wingo Journal: Nat Neurosci Date: 2020-05-18 Impact factor: 24.884
Authors: Michael Tran Duong; Ilya M Nasrallah; David A Wolk; Catherine C Y Chang; Ta-Yuan Chang Journal: Front Aging Neurosci Date: 2021-03-25 Impact factor: 5.750
Authors: Farzaneh Rahmani; Marina Nguyen; Charles D Chen; Nicole McKay; Aylin Dincer; Nelly Joseph-Mathurin; Gengsheng Chen; Jingxia Liu; Hilary L P Orlowski; John C Morris; Tammie L S Benzinger Journal: Alzheimers Res Ther Date: 2022-02-11 Impact factor: 8.823
Authors: Koung Mi Kang; Min Soo Byun; Jun Ho Lee; Dahyun Yi; Hye Jeong Choi; Eunjung Lee; Younghwa Lee; Jun-Young Lee; Yu Kyeong Kim; Bo Kyung Sohn; Chul-Ho Sohn; Dong Young Lee Journal: Alzheimers Res Ther Date: 2020-09-10 Impact factor: 6.982